Goldman Sachs has set a Neutral target for Bayer at €31. Despite continuous legal and financial challenges, Bayer managed to retain certain investor confidence with its robust Q1 performance and internal restructuring focus, supported by shareholder Harris. Bayer is delving into self-organization, planning management job cuts, and slashing its dividend by 95% to tackle its debt burden. However, some setbacks have hit Bayer hard recently. Monsanto's appeal win initially triggered a surge in Bayer's shares but the triumph was short-lived due to trial termination of asundexian and shares plummeting to an 18-year low. Bayer is also dealing with Roundup related legal battles, facing a $2.25 billion penalty, leading to stock plunge post-verdict. Metagenomi, backed by Moderna and Bayer, saw its stock drop by 32% on its Nasdaq debut. Issues with Bayer’s Weedkiller other than Roundup and the blood-thinning drug trial halt have also negatively impacted the shares. Closing the year on a low note, Bayer has lost more than 28% in 2023 and is set for further losses based on their weak 2024 preparations.
BAYER Stocks News Analytics from Tue, 22 Aug 2023 07:00:00 GMT to Sat, 01 Jun 2024 00:33:00 GMT - Rating -7 - Innovation 0 - Information 8 - Rumor -6